Sodium-Glucose Cotransporter-2 Inhibitors (SGLT2i) – empagliflozin

These flashcards cover key information regarding Sodium-Glucose Cotransporter-2 Inhibitors, specifically empagliflozin, including its uses, side effects, contraindications, precautions, interactions, administration, and monitoring requirements.

SGLT2 inhibitors

A class of medications used primarily to treat Type 2 Diabetes Mellitus by preventing glucose reabsorption in the kidneys.

Therapeutic Uses of empagliflozin

Indicated for Type 2 Diabetes Mellitus, heart failure, and cardiovascular disease.

Adverse Drug Reactions

Potential negative effects include diabetic ketoacidosis, hypoglycemia, dehydration, hypotension, fractures, and acute kidney injury.

Client Instructions for empagliflozin

Patients should notify their provider of any adverse effects, monitor blood pressure and glucose, maintain hydration, and watch for genital yeast infections and UTIs.

Contraindications for empagliflozin

Not recommended for patients with Type 1 diabetes mellitus and renal failure.

Precautions with empagliflozin

Includes risk of diabetic ketoacidosis, caution with reduced caloric intake, fasting, hypotension, and moderate renal impairments.

Drug Interactions

Include potential interactions with diuretics, anti-hyperglycemics, oral hypoglycemics, salicylates, and MAOIs.

Administration of empagliflozin

Orally administered, taken once a day, with or without food.

Monitoring for SGLT2i therapy

Important to monitor blood glucose levels, LDL levels, kidney function, manifestations of dehydration, diabetic ketoacidosis, and urinary tract infections (UTIs).